短期间歇性缺氧暴露呼吸不良和疲劳在COVID-19的后急性后果:一个随机对照研究
Shiqian Zha1, Xu Liu1, Yan Yao2
1Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Respiratory medicine
|August 10, 2024
概括
间歇性缺氧暴露 (IHE) 显著改善了COVID-19 (PASC) 后急性后续症患者的肺功能,并减少了疲劳. 这种新的治疗方法为PASC恢复提供了希望.
科学领域:
- 肺部病理学 肺部病理学
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
背景情况:
- COVID-19 (PASC) 后急性后果是一个重大的全球健康挑战,没有确定的治疗方法.
- PASC的特点是持续的症状,如呼吸障碍和疲劳,影响患者的生活质量.
研究的目的:
- 调查间歇性缺氧暴露 (IHE) 在缓解PASC患者呼吸障碍和疲劳方面的疗效.
- 为了比较IHE与normoxia暴露 (NE) 对呼吸功能和患者报告的结果的影响.
主要方法:
- 进行了一项前性随机对照试验,涉及95名PASC患者.
- 参与者接受了IHE (5分钟的低氧与5分钟的正常空气交替) 或NE与常规治疗一起.
- 结果包括6分钟步行距离 (6MWD),螺旋计,呼吸障碍尺度 (Borg,mMRC) 和疲劳尺度 (FAS,CFQ-11).
主要成果:
- 与NE组相比,IHE组在6MWD,螺旋测量 (FVC,FEV1) 中显著改善,呼吸障碍和疲劳减少 (p <0.05).
- 较长的IHE持续时间 (≥10天) 表明对功能和症状结果的积极影响更大.
- 在干预期间没有报告任何严重不良事件.
结论:
- 间歇性缺氧暴露是一种有前途的治疗策略,可以改善呼吸功能,减轻PASC患者的呼吸困难和疲劳.
- 需要进一步的大规模前性研究来验证这些发现并建立最佳的IHE协议.
更多相关视频
相关概念视频
Acute Respiratory Failure-II
192
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
192
Acute Respiratory Failure-IV
133
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
133
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
191
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
191
Acute Respiratory Failure-I
184
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
184
Pneumothorax-I
186
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
186
Acute Respiratory Failure-III
167
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
167


